In the therapy set, plasma PMP and MKMP levels were increased significantly in ITP patients who responded to TPO-RA treatment (p < 0.05 and p < 0.005, respectively) (Figure 4A,B). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.